These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 3257280)

  • 1. New Haemophilus influenzae vaccine licensed.
    Marwick C
    JAMA; 1988 Feb; 259(5):643, 647. PubMed ID: 3257280
    [No Abstract]   [Full Text] [Related]  

  • 2. Haemophilus influenzae type b vaccine.
    Anderson P; Pichichero ME
    Pediatrics; 1989 Jan; 83(1):145-6. PubMed ID: 2909967
    [No Abstract]   [Full Text] [Related]  

  • 3. Pediatrics academy issues recommendations on use of Haemophilus influenzae type b conjugate vaccine.
    Clin Pharm; 1988 Sep; 7(9):634. PubMed ID: 3266482
    [No Abstract]   [Full Text] [Related]  

  • 4. Polysaccharide-protein conjugate vaccines for the prevention of Haemophilus influenzae type b disease.
    Weinberg GA; Granoff DM
    J Pediatr; 1988 Oct; 113(4):621-31. PubMed ID: 3050001
    [No Abstract]   [Full Text] [Related]  

  • 5. Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in vaccinated children who developed Haemophilus disease.
    Weinberg GA; Murphy TV; Granoff DM
    Pediatrics; 1990 Oct; 86(4):617-20. PubMed ID: 2216629
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention of Haemophilus influenzae type b disease: vaccines and passive prophylaxis.
    Wenger JD; Ward JI; Broome CV
    Curr Clin Top Infect Dis; 1989; 10():306-39. PubMed ID: 2679698
    [No Abstract]   [Full Text] [Related]  

  • 7. [Conjugated vaccines against Haemophilus influenzae type b].
    Rümke HC; Poolman JT
    Ned Tijdschr Geneeskd; 1991 Jan; 135(1):4-7. PubMed ID: 2012643
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjugated Haemophilus influenzae type b vaccine.
    Med Lett Drugs Ther; 1988 Apr; 30(764):47-8. PubMed ID: 3258400
    [No Abstract]   [Full Text] [Related]  

  • 10. Vaccines for Haemophilus influenzae type b as models for an otitis vaccine.
    Mäkelä PH; Käyhty H; Peltola H; Eskola J
    Pediatr Infect Dis J; 1989 Jan; 8(1 Suppl):S73-5. PubMed ID: 2648298
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunogenicity of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in 3- to 17-month-old infants with sickle cell diseases.
    Marcinak JF; Frank AL; Labotka RL; Rao S; Drawhorn L; Dampier C; Frisone LR; Yogev R; McVerry P
    J Pediatr; 1991 Jan; 118(1):69-71. PubMed ID: 1986101
    [No Abstract]   [Full Text] [Related]  

  • 12. Responses of children to booster immunization with their primary conjugate Haemophilus influenzae type B vaccine or with polyribosylribitol phosphate conjugated with diphtheria toxoid.
    Decker MD; Edwards KM; Bradley R; Palmer P
    J Pediatr; 1993 Mar; 122(3):410-3. PubMed ID: 8441096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statement on Haemophilus influenzae type b conjugate vaccines for use in infants and children.
    CMAJ; 1993 Jan; 148(2):199-214. PubMed ID: 8452591
    [No Abstract]   [Full Text] [Related]  

  • 14. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. Recommendations of the immunization practices advisory committee (ACIP).
    MMWR Recomm Rep; 1991 Jan; 40(RR-1):1-7. PubMed ID: 1899280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenuria after receipt of Haemophilus b diphtheria toxoid conjugate vaccine.
    Scheifele D; Bjornsen GL; Arcand T; Jacobsen K
    Pediatr Infect Dis J; 1989 Dec; 8(12):887-8. PubMed ID: 2626290
    [No Abstract]   [Full Text] [Related]  

  • 16. Post-marketing surveillance of adverse events following ProHIBit vaccine--British Columbia.
    Meekison W; Hutcheon M; Guasparini R; Arnott M; Scheifele D; Grace M; Humphreys G; Barreto L
    Can Dis Wkly Rep; 1989 Jul; 15(28):143-5. PubMed ID: 2791073
    [No Abstract]   [Full Text] [Related]  

  • 17. Immune response of young children vaccinated with Haemophilus influenzae type b conjugate vaccines.
    Madore DV; Phipps DC; Eby R; Johnson CL; Smith DH
    Contrib Microbiol Immunol; 1989; 10():125-50. PubMed ID: 2684505
    [No Abstract]   [Full Text] [Related]  

  • 18. Commentary: results of efficacy trials in Alaska and Finland of Haemophilus influenzae type b conjugate vaccine.
    Ward J
    Pediatrics; 1990 Apr; 85(4 Pt 2):667. PubMed ID: 2179858
    [No Abstract]   [Full Text] [Related]  

  • 19. Haemophilus b oligosaccharide-CRM197 and other Haemophilus b conjugate vaccines: a status report.
    Smith DH; Madore DV; Eby RJ; Anderson PW; Insel RA; Johnson CL
    Adv Exp Med Biol; 1989; 251():65-82. PubMed ID: 2692432
    [No Abstract]   [Full Text] [Related]  

  • 20. Background and indications for Haemophilus influenzae type b vaccines consisting of capsular antigen coupled to protein carriers.
    Anderson PW; Stein EC; Insel RA
    Contrib Microbiol Immunol; 1989; 10():115-24. PubMed ID: 2684504
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.